Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 66

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 66
---
 Nasdaq Global Market on November 4, 2025, and after deducting commissions and estimated aggregate offering expenses payable by us, our net tangible book value as of September 30, 2025 would have been $355.4 million, or $1.57 per share of common stock. This represents an immediate increase in the net tangible book value of $0.67 per share to our existing stockholders and immediate dilution of $2.73 in net tangible book value per share to new investors in this offering. The following table illustrates this per share dilution:

| Assumed offering price per share                                                                              |     |   |      |     | $ | 4.30 |
| Net tangible book value per share as of September 30, 2025                                                    |     | $ | 0.90 |     |   |      |
| Increase in net tangible book value per share attributable to sale of shares of common stock in this offering |     |   | 0.67 |     |   |      |
| As adjusted net tangible book value per share after this offering                                             |     |   |      |     |   | 1.57 |
| Dilution in net tangible book value per share to new investors purchasing shares in this offering             |     |   |      |     | $ | 2.73 |

The table above assumes for illustrative purposes that an aggregate of 46,511,627 shares of our common stock are sold pursuant to this prospectus at a price of $4.30 per share, the last reported sale price of our common stock on The Nasdaq Global Market on November 4, 2025, for aggregate gross proceeds of $200.0 million. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price to $5.30 per share, assuming all of our common stock in the aggregate amount of $200.0 million is sold at that price, would result in an adjusted net tangible book value per share after the offering of $1.63 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $3.67 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price to $3.